Why it matters
RPM adoption is being constrained not only by reimbursement levels but by proof of appropriate use, operational integrity, billing compliance, and demonstrable care delivery.
Decision implication
Add compliance/appropriate-use evidence to the RPM adoption diagnostic and treat unusually weak component delivery as a risk signal for vendors and practices.
Who or what is affected
- CMS
- OIG
- RPM vendors
- clinicians
- medical practices
- Medicare beneficiaries
Evidence and sources
E5 — CMS/OIG official sources
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- Final CY 2027 rules
- enforcement
- audit patterns
- billing trends
- outcome data.